Is Associated with Bucillamine-Induced Proteinuria in Japanese Rheumatoid Arthritis Patients

Background Drug-induced proteinuria can occur in rheumatoid arthritis (RA) patients treated with d-penicillamine, gold salts, or bucillamine (Buc), and represents a drug hypersensitivity reaction. Striking associations of human leukocyte antigen (HLA) alleles with adverse reactions have recently bee...

Full description

Bibliographic Details
Main Authors: Hiroshi Furukawa, Shomi Oka, Kota Shimada, Shoji Sugii, Atsushi Hashimoto, Akiko Komiya, Naoshi Fukui, Taiichiro Miyashita, Kiyoshi Migita, Akiko Suda, Shouhei Nagaoka, Naoyuki Tsuchiya, Shigeto Tohma
Format: Article
Language:English
Published: SAGE Publishing 2014-01-01
Series:Biomarker Insights
Online Access:https://doi.org/10.4137/BMI.S13654
Description
Summary:Background Drug-induced proteinuria can occur in rheumatoid arthritis (RA) patients treated with d-penicillamine, gold salts, or bucillamine (Buc), and represents a drug hypersensitivity reaction. Striking associations of human leukocyte antigen (HLA) alleles with adverse reactions have recently been reported for many drugs. Methods We investigated the association of HLA class II with Buc-induced proteinuria (BI-Pro) in 485 Japanese RA patients treated with Buc, of whom 25 had developed BI-Pro. Results and Conclusion This preliminary study showed a highly significant association of DRB1*08:02 with BI-Pro ( P = 1.09 × 10 −6 , corrected P [ Pc ] = 1.96 × 10 −5 , odds ratio [OR] 25.17, 95% confidence interval [CI] 7.98-79.38). DQB1*04:02 was also significantly associated with increased risk of BI-Pro ( P = 2.44 × 10 −5 , Pc = 2.69 × 10 −4 , OR 10.35, 95%CI 3.99–26.83). These findings provide useful information for promoting personalized medicine for RA.
ISSN:1177-2719